Society for Medical Decision Making

Migraine headaches are associated with significant social and economic burdens.  Traditional treatments for migraine prevention have included divalproex, topiramate, and beta-blockers, but innovative pharmaceutical agents such as calcitonin gene-related peptide receptors monoclonal antibodies have changed the treatment landscape with their clinical effectiveness.

Despite their efficacy, the high costs of calcitonin gene-related peptide receptors monoclonal antibodies have raised concerns about the value of these medications to treat episodic migraine. To address this issue, we developed a hybrid decision-Markov model to evaluate the cost-effectiveness of two calcitonin gene-related peptide receptors monoclonal antibodies, eptinezumab and erenumab, on migraine prevention for individuals with episodic migraine in the United States.

REGISTER HERE